Abridge

What is Abridge and who sells it?

Abridge describes its product as AI-powered clinical documentation "built for accuracy", organised into three experiences (clinicians, revenue cycle, nursing) plus an Assistant and a module called Care Signals (Abridge website, read October 2026). The core function is ambient documentation: it listens to a visit and drafts the note.

The company is Abridge AI, Inc., based in Pittsburgh. It was founded in 2018 by Shivdev Rao, a cardiologist who is CEO, with Florian Metze and Sandeep Konam, and it grew out of the Pittsburgh Health Data Alliance of the University of Pittsburgh, UPMC and Carnegie Mellon (Contrary Research).

Funding is large and the press figures disagree in places. TechCrunch reported a $250M Series D in February 2025 at $2.75B and a $300M Series E in June 2025 at $5.3B, led by Andreessen Horowitz with Khosla. Sacra reports a further $316M extension in April 2026, while Tracxn dates a $316M round to June 2025. Total funding is quoted between $758M and $830M depending on the source. No ownership changes are reported. The vendor's page states "Best in KLAS" for ambient AI in 2025 and 2026, which is vendor-presented recognition.

What does Abridge do well?

Its strongest feature is traceability. Abridge calls it Linked Evidence: statements in the note are mapped back to the transcript and audio, so a clinician can check where a line came from (Abridge product page). That is the vendor's description, and it was not tested here. The clinician who signs the note carries the cost of an unchecked error, which is why traceability is the feature to ask about in a demo.

The second strength is Epic depth. TechCrunch describes Abridge as the first Epic "Pal" partner, in August 2023, and the vendor's own press release describes "Abridge Inside" running in Epic from Haiku to Hyperdrive at Emory. If your health system lives in Epic, that integration path is a real reason to shortlist the product.

Breadth is the third. Beyond physician notes, the site lists revenue-cycle documentation, nursing documentation and care-signal modules. Language coverage is stated as 14 or more in an older press release, and an AltaMed deployment announcement cites 28 languages. The two figures reflect different dates and deployments, so we do not give a single number.

The vendor's home page makes these customer claims: UW Health with more than 800 providers and 30 minutes a day of documentation time saved, Inova with 9,400 or more clinicians across 40 or more specialties, and 95% retention at Akron Children's.

On security, the Trust Center lists CCPA, HIPAA, SOC 2 Type 1 and Type 2, and TX-RAMP, with the SOC 2 report available on request (Abridge Trust Center), and a standard Business Associate Agreement is offered on the product page. The Trust Center does not list HITRUST or ISO 27001.

Where does Abridge fall short?

The sharpest criticism comes from working clinicians, and it is about the draft note. A physician on r/medicine (March 2026) called the HPI inaccurate and amateurish, wrote that the note "commonly contains inaccuracies", and said it misses exam findings. On r/emergencymedicine the same month, a physician whose department had just integrated Abridge into Epic and used it through Haiku wrote that they spent more time proofreading and editing than it would take to just write the note.

Two threads do not make a rate. Several other threads are neutral: an emergency department keeping human scribes while Abridge rolls out (October 2025), a department moving to Abridge on Epic asking for pros and cons (May 2026), and a family physician asking which scribe is best among DAX, Abridge, Suno and Vero (December 2025). A family medicine thread from August 2025, "Piloting Abridge, the AI scribe", describes a week of use on Epic with Haiku.

The research literature supports caution in general, not about Abridge specifically. A narrative review reports frequent omissions and occasional clinically significant hallucinations across ambient scribes (PMC12973079). No peer-reviewed accuracy study of Abridge alone is published.

Price is the other gap. There is no public price, and the pricing page lists no plans or trial. Procurement is a sales process, and one roundup describes a 12-month minimum and three to six months to buy. That roundup is third-party and should be read that way.

How does Abridge compare with DAX Copilot, Heidi and the rest?

The comparison set is the one Reddit uses: DAX Copilot (now Microsoft Dragon Copilot), Heidi Health, Suki, Nabla, Ambience, DeepScribe, Commure, Vero Scribe and Freed. In a February 2026 r/healthIT thread, a poster described Abridge as "one of the players in ambulatory care" and wrote that for Heidi "several ppl said it's expensive".

Against DAX Copilot, the contest is about ecosystem. Both are enterprise products sold by quote, and both integrate with Epic. DAX comes from Microsoft with a Nuance heritage and a security white paper that cites a HITRUST-certified Azure environment, while Abridge is a venture-backed specialist. Neither publishes a price. Third-party estimates for Abridge run from about $208 to $600 per clinician per month, plus implementation. DAX estimates run from about $150 to $600 or more. The estimates come from vendors who sell competing scribes, so they show the width of the uncertainty and are not quotes.

Against Heidi, the contest is about buyer type. Heidi publishes a free tier and a trial and suits an individual clinician. Abridge publishes neither. One r/medicine poster in October 2023 noted that Abridge then offered individual licences without EMR integration while warning their institution against buying its own scribe. Whether that individual route still exists is not confirmed.

By situation, Abridge fits when the decision is institutional and Epic is the record. It fits poorly when you need to start this week, pay by card, or see a price before talking to sales.

What does the evidence say about Abridge?

The evidence is partial and not Abridge-specific. The best-known study is a multi-site JAMA analysis of 8,581 clinicians at five health systems using Ambience, DAX or Abridge (reported by Healthcare Dive). It found 13.4 fewer EHR minutes and 16.0 fewer documentation minutes per 8 scheduled hours. After-hours EHR time did not fall significantly overall, and only about 32% of adopters used the scribe in at least half of their visits. It is a multi-vendor result and cannot be credited to Abridge alone.

Two 2025 papers concern ambient tools in practice. An observational study in Digital Health (PMID 41323090) examined changes in EHR documentation metrics after an ambient listening tool was introduced in primary care. A quality-improvement survey in JAMIA Open (PMID 39991073) assessed clinician perspectives on workload, burnout and job satisfaction. Separately, a narrative review (PMC12973079) attributes to a JAMIA Open study from February 2025 (Albrecht et al.) a finding that 73% of Abridge users reported less documentation outside clinical hours. The figure is the review's account of the paper.

Who is Abridge for?

• A CMIO at an Epic health system rolling out ambient documentation to hundreds of clinicians, with a procurement team and a pilot plan, is the intended buyer.
• An emergency department that already has human scribes and is weighing a transition. The two March 2026 threads say to pilot with your own note templates and measure editing time before you commit.
• A nursing or revenue-cycle leader who wants documentation beyond physician notes in the same vendor.

Abridge does not fit a solo practitioner or a two-physician clinic, a clinician outside Epic who needs write-back, which is not documented, or anyone who needs a published price before a first call. Self-serve scribes are cheaper to try.

The verdict

Abridge is a credible enterprise scribe with a documented Epic path. The proof of its benefit is shared across vendors, and the user reports that exist are critical or neutral. Pilot it with your own clinicians, count the minutes they spend editing, and get the price in writing: there is no public list as of October 2026, and third-party estimates of about $208 to $600 per clinician per month plus implementation are not Abridge figures.